Imunização genital de bezerras com uma cepa recombinante do herpesvírus bovino tipo 1 defectiva na glicoproteína E
Ano de defesa: | 2009 |
---|---|
Autor(a) principal: | |
Orientador(a): | |
Banca de defesa: | , |
Tipo de documento: | Dissertação |
Tipo de acesso: | Acesso aberto |
Idioma: | por |
Instituição de defesa: |
Universidade Federal de Santa Maria
|
Programa de Pós-Graduação: |
Programa de Pós-Graduação em Medicina Veterinária
|
Departamento: |
Medicina Veterinária
|
País: |
BR
|
Palavras-chave em Português: | |
Palavras-chave em Inglês: | |
Área do conhecimento CNPq: | |
Link de acesso: | http://repositorio.ufsm.br/handle/1/10035 |
Resumo: | We herein report an evaluation of the attenuation and protection conferred by genital vaccination of heifers with a bovine herpesvirus type 1 strain (BoHV-1) defective in the glycoprotein E (SV265gE-). A group of six seronegative heifers was vaccinated with SV265gE- in the submucosa of the vulva (group IV; 106.9TCID50); four heifers were vaccinated intramuscularly (group IM; 107.6TCID50) and four heifers remained as nonvaccinated controls. Heifers vaccinated IV developed mild and transient local edema and hyperemia and shed low amounts of virus for a few days after vaccination, yet a sentinel heifer maintained in close contact did not seroconvert. Attempts to reactivate the vaccine virus in two IV vaccinated heifers by intravenous administration of dexamethasone (0.5 mg.kg-1) at day 65 post-vaccination (pv) failed since no virus shedding, recrudescence of genital signs or seroconversion were observed. At day 65 pv, all vaccinated and control heifers were challenged by genital inoculation of a highly virulent BoHV-1.2 isolate (SV-56/90, 107.4TCID50/animal). After challenge, virus shedding was detected in genital secretions of control animals for 8.2 days (8 9 days); in the IM group for 6.2 days (5 8 days) and during 5.2 days (5 6 days) in the IV group. Control non-vaccinated heifers developed moderate (2/4) or severe (2/4) vulvovaginitis lasting 9 to 14 days ( 11.2 days). The disease was characterized by vulvar edema, vulvovestibular congestion, small vesicles progressing to coalescence and erosions, fibrinonecrotic plaques and fibrinopurulent exsudate. IM vaccinated heifers developed mild (1/3) or moderate (3/4) genital lesions, lasting 10 to 13 days ( 11.5 days); and IV vaccinated heifers developed mild and transient (3/4) or mild to moderate genital signs (1/4), lasting 4 to 8 days ( 5.5 days). Clinical examination of the animals after challenge revealed that vaccination by both routes conferred some degree of protection, yet IV vaccination was clearly more effective in reducing the duration of virus shedding, the severity and duration of clinical disease. Taken together, these results demonstrate that SV265gE- is sufficiently attenuated upon IV vaccination in a low-titer dosis, is not reactivated after corticosteroid treatment and lastly, and more importantly, confers local protection upon challenge with a high titer of a virulent heterologous BoHV-1 isolate. Thus, this immunization strategy may be considered for the prevention of BoHV-1-associated genital disease in the field. |
id |
UFSM-20_98eea3d6ce2d2b2f48fc5f37e27ca05a |
---|---|
oai_identifier_str |
oai:repositorio.ufsm.br:1/10035 |
network_acronym_str |
UFSM-20 |
network_name_str |
Manancial - Repositório Digital da UFSM |
repository_id_str |
|
spelling |
2017-06-142017-06-142009-03-03WEISS, Marcelo. Genital immunization of heifers with a recombinant strain of bovine herpesvirus type 1 defective in the glycoprotein E. 2009. 42 f. Dissertação (Mestrado em Medicina Veterinária) - Universidade Federal de Santa Maria, Santa Maria, 2009.http://repositorio.ufsm.br/handle/1/10035We herein report an evaluation of the attenuation and protection conferred by genital vaccination of heifers with a bovine herpesvirus type 1 strain (BoHV-1) defective in the glycoprotein E (SV265gE-). A group of six seronegative heifers was vaccinated with SV265gE- in the submucosa of the vulva (group IV; 106.9TCID50); four heifers were vaccinated intramuscularly (group IM; 107.6TCID50) and four heifers remained as nonvaccinated controls. Heifers vaccinated IV developed mild and transient local edema and hyperemia and shed low amounts of virus for a few days after vaccination, yet a sentinel heifer maintained in close contact did not seroconvert. Attempts to reactivate the vaccine virus in two IV vaccinated heifers by intravenous administration of dexamethasone (0.5 mg.kg-1) at day 65 post-vaccination (pv) failed since no virus shedding, recrudescence of genital signs or seroconversion were observed. At day 65 pv, all vaccinated and control heifers were challenged by genital inoculation of a highly virulent BoHV-1.2 isolate (SV-56/90, 107.4TCID50/animal). After challenge, virus shedding was detected in genital secretions of control animals for 8.2 days (8 9 days); in the IM group for 6.2 days (5 8 days) and during 5.2 days (5 6 days) in the IV group. Control non-vaccinated heifers developed moderate (2/4) or severe (2/4) vulvovaginitis lasting 9 to 14 days ( 11.2 days). The disease was characterized by vulvar edema, vulvovestibular congestion, small vesicles progressing to coalescence and erosions, fibrinonecrotic plaques and fibrinopurulent exsudate. IM vaccinated heifers developed mild (1/3) or moderate (3/4) genital lesions, lasting 10 to 13 days ( 11.5 days); and IV vaccinated heifers developed mild and transient (3/4) or mild to moderate genital signs (1/4), lasting 4 to 8 days ( 5.5 days). Clinical examination of the animals after challenge revealed that vaccination by both routes conferred some degree of protection, yet IV vaccination was clearly more effective in reducing the duration of virus shedding, the severity and duration of clinical disease. Taken together, these results demonstrate that SV265gE- is sufficiently attenuated upon IV vaccination in a low-titer dosis, is not reactivated after corticosteroid treatment and lastly, and more importantly, confers local protection upon challenge with a high titer of a virulent heterologous BoHV-1 isolate. Thus, this immunization strategy may be considered for the prevention of BoHV-1-associated genital disease in the field.O presente estudo relata a avaliação da atenuação e proteção conferida pela vacinação intravaginal de bezerras com uma cepa recombinante do herpesvírus bovino tipo 1 (BoHV-1) defectiva na glicoproteína E (SV265gE-). Um grupo de seis bezerras foi vacinado com a cepa SV265gE- na submucosa da vulva (grupo IV; 106,9TCID50); quatro bezerras foram vacinadas pela via intramuscular (grupo IM; 107,6TCID50) e quatro bezerras permaneceram como controles não-vacinadas. As bezerras vacinadas pela via IV apresentaram edema e hiperemia leve e transitório na vulva; excretaram pequenas quantidades de vírus nas secreções, mas não transmitiram o vírus a uma bezerra sentinela mantida em contato. A tentativa de reativar o vírus vacinal em duas bezerras vacinadas IV pela administração intravenosa de dexametasona (0.5 mg.kg-1) no dia 65 pós-vacinação (pv) não resultou em excreção viral, recrudescência clínica ou soroconversão. No dia 65 pv, as bezerras vacinadas e as controles foram desafiadas pela inoculação genital da cepa SV-56/90 do BoHV-1.2 (107,4TCID50/animal). Após o desafio, o vírus foi detectado nas secreções das bezerras controles por 8 a 9 dias ( 8,2 dias); nas bezerras do grupo IM por 5 a 8 dias ( 6,2) e nas do grupo IV por 5 a 6 dias ( 5,2 dias). As bezerras controle desenvolveram vulvovaginite moderada (2/4) ou severa (2/4) com duração média de 11,2 dias (9 14). A enfermidade caracterizou-se por edema vulvar, congestão vulvovestibular, formação de pequenas vesículas, pústulas, que progrediram até coalescerem, erosões, placas fibrinonecróticas recobertas com exsudato fibrinopurulento. As bezerras do grupo IM desenvolveram vulvovaginite leve (1/3) ou moderada (3/4), com duração média de 11,5 dias (10 13 dias); enquanto as bezerras do grupo IV desenvolveram sinais genitais leves e transitórios (3/4) ou moderados (1/4), com duração média de 5,5 dias (4 8). A avaliação clínica pós-desafio demonstrou que a vacinação pelas duas vias (IM e IV) conferiu proteção, mas a vacinação IV foi mais efetiva na redução do tempo de excreção viral e na redução da severidade e duração dos sinais clínicos. Assim, esses resultados demonstram que a cepa SV265gE- é suficientemente atenuada para vacinação IV em dose baixa, não é reativada pela administração de dexametasona e, principalmente, confere proteção adequada frente a desafio genital com uma dose alta de uma cepa heteróloga altamente virulenta. Portanto, essa estratégia de imunização pode ser considerada para a prevenção das perdas reprodutivas causadas pela infecção genital pelo BoHV-1.Conselho Nacional de Desenvolvimento Científico e Tecnológicoapplication/pdfporUniversidade Federal de Santa MariaPrograma de Pós-Graduação em Medicina VeterináriaUFSMBRMedicina VeterináriaHerpesvírus bovinoBoHV-1.2VulvovaginiteVacinaProteção vacinalBovine herpesvirusVulvovaginitisGenital infectionVaccineCNPQ::CIENCIAS AGRARIAS::MEDICINA VETERINARIAImunização genital de bezerras com uma cepa recombinante do herpesvírus bovino tipo 1 defectiva na glicoproteína EGenital immunization of heifers with a recombinant strain of bovine herpesvirus type 1 defective in the glycoprotein Einfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisFlores, Eduardo Furtadohttp://lattes.cnpq.br/0446078331070694Vogel, Fernanda Silveira Flôreshttp://lattes.cnpq.br/9676833435314493Caron, Luizinhohttp://lattes.cnpq.br/9334336945441958http://lattes.cnpq.br/9128802775921539Weiss, Marcelo5005000000074005005005005001cd49172-b6b6-4db1-b27e-daf2b145ba82d5f9666a-b82e-4a5c-96d1-3b2f85651db00aa5402c-d907-49de-b28f-597e39e788d7c648a19e-e9b3-43c3-95bf-791bb03d4b80info:eu-repo/semantics/openAccessreponame:Manancial - Repositório Digital da UFSMinstname:Universidade Federal de Santa Maria (UFSM)instacron:UFSMORIGINALMARCELOWEISS.pdfapplication/pdf376500http://repositorio.ufsm.br/bitstream/1/10035/1/MARCELOWEISS.pdf66fd01e5afabbdf077cac1995145c39fMD51TEXTMARCELOWEISS.pdf.txtMARCELOWEISS.pdf.txtExtracted texttext/plain83599http://repositorio.ufsm.br/bitstream/1/10035/2/MARCELOWEISS.pdf.txt39de5878e532784c61abecd9127f7077MD52THUMBNAILMARCELOWEISS.pdf.jpgMARCELOWEISS.pdf.jpgIM Thumbnailimage/jpeg4856http://repositorio.ufsm.br/bitstream/1/10035/3/MARCELOWEISS.pdf.jpga6a8b3a4f4fdb063c5131eae8d03eaacMD531/100352023-05-03 09:27:23.846oai:repositorio.ufsm.br:1/10035Repositório Institucionalhttp://repositorio.ufsm.br/PUBhttp://repositorio.ufsm.br/oai/requestopendoar:39132023-05-03T12:27:23Manancial - Repositório Digital da UFSM - Universidade Federal de Santa Maria (UFSM)false |
dc.title.por.fl_str_mv |
Imunização genital de bezerras com uma cepa recombinante do herpesvírus bovino tipo 1 defectiva na glicoproteína E |
dc.title.alternative.eng.fl_str_mv |
Genital immunization of heifers with a recombinant strain of bovine herpesvirus type 1 defective in the glycoprotein E |
title |
Imunização genital de bezerras com uma cepa recombinante do herpesvírus bovino tipo 1 defectiva na glicoproteína E |
spellingShingle |
Imunização genital de bezerras com uma cepa recombinante do herpesvírus bovino tipo 1 defectiva na glicoproteína E Weiss, Marcelo Herpesvírus bovino BoHV-1.2 Vulvovaginite Vacina Proteção vacinal Bovine herpesvirus Vulvovaginitis Genital infection Vaccine CNPQ::CIENCIAS AGRARIAS::MEDICINA VETERINARIA |
title_short |
Imunização genital de bezerras com uma cepa recombinante do herpesvírus bovino tipo 1 defectiva na glicoproteína E |
title_full |
Imunização genital de bezerras com uma cepa recombinante do herpesvírus bovino tipo 1 defectiva na glicoproteína E |
title_fullStr |
Imunização genital de bezerras com uma cepa recombinante do herpesvírus bovino tipo 1 defectiva na glicoproteína E |
title_full_unstemmed |
Imunização genital de bezerras com uma cepa recombinante do herpesvírus bovino tipo 1 defectiva na glicoproteína E |
title_sort |
Imunização genital de bezerras com uma cepa recombinante do herpesvírus bovino tipo 1 defectiva na glicoproteína E |
author |
Weiss, Marcelo |
author_facet |
Weiss, Marcelo |
author_role |
author |
dc.contributor.advisor1.fl_str_mv |
Flores, Eduardo Furtado |
dc.contributor.advisor1Lattes.fl_str_mv |
http://lattes.cnpq.br/0446078331070694 |
dc.contributor.referee1.fl_str_mv |
Vogel, Fernanda Silveira Flôres |
dc.contributor.referee1Lattes.fl_str_mv |
http://lattes.cnpq.br/9676833435314493 |
dc.contributor.referee2.fl_str_mv |
Caron, Luizinho |
dc.contributor.referee2Lattes.fl_str_mv |
http://lattes.cnpq.br/9334336945441958 |
dc.contributor.authorLattes.fl_str_mv |
http://lattes.cnpq.br/9128802775921539 |
dc.contributor.author.fl_str_mv |
Weiss, Marcelo |
contributor_str_mv |
Flores, Eduardo Furtado Vogel, Fernanda Silveira Flôres Caron, Luizinho |
dc.subject.por.fl_str_mv |
Herpesvírus bovino BoHV-1.2 Vulvovaginite Vacina Proteção vacinal |
topic |
Herpesvírus bovino BoHV-1.2 Vulvovaginite Vacina Proteção vacinal Bovine herpesvirus Vulvovaginitis Genital infection Vaccine CNPQ::CIENCIAS AGRARIAS::MEDICINA VETERINARIA |
dc.subject.eng.fl_str_mv |
Bovine herpesvirus Vulvovaginitis Genital infection Vaccine |
dc.subject.cnpq.fl_str_mv |
CNPQ::CIENCIAS AGRARIAS::MEDICINA VETERINARIA |
description |
We herein report an evaluation of the attenuation and protection conferred by genital vaccination of heifers with a bovine herpesvirus type 1 strain (BoHV-1) defective in the glycoprotein E (SV265gE-). A group of six seronegative heifers was vaccinated with SV265gE- in the submucosa of the vulva (group IV; 106.9TCID50); four heifers were vaccinated intramuscularly (group IM; 107.6TCID50) and four heifers remained as nonvaccinated controls. Heifers vaccinated IV developed mild and transient local edema and hyperemia and shed low amounts of virus for a few days after vaccination, yet a sentinel heifer maintained in close contact did not seroconvert. Attempts to reactivate the vaccine virus in two IV vaccinated heifers by intravenous administration of dexamethasone (0.5 mg.kg-1) at day 65 post-vaccination (pv) failed since no virus shedding, recrudescence of genital signs or seroconversion were observed. At day 65 pv, all vaccinated and control heifers were challenged by genital inoculation of a highly virulent BoHV-1.2 isolate (SV-56/90, 107.4TCID50/animal). After challenge, virus shedding was detected in genital secretions of control animals for 8.2 days (8 9 days); in the IM group for 6.2 days (5 8 days) and during 5.2 days (5 6 days) in the IV group. Control non-vaccinated heifers developed moderate (2/4) or severe (2/4) vulvovaginitis lasting 9 to 14 days ( 11.2 days). The disease was characterized by vulvar edema, vulvovestibular congestion, small vesicles progressing to coalescence and erosions, fibrinonecrotic plaques and fibrinopurulent exsudate. IM vaccinated heifers developed mild (1/3) or moderate (3/4) genital lesions, lasting 10 to 13 days ( 11.5 days); and IV vaccinated heifers developed mild and transient (3/4) or mild to moderate genital signs (1/4), lasting 4 to 8 days ( 5.5 days). Clinical examination of the animals after challenge revealed that vaccination by both routes conferred some degree of protection, yet IV vaccination was clearly more effective in reducing the duration of virus shedding, the severity and duration of clinical disease. Taken together, these results demonstrate that SV265gE- is sufficiently attenuated upon IV vaccination in a low-titer dosis, is not reactivated after corticosteroid treatment and lastly, and more importantly, confers local protection upon challenge with a high titer of a virulent heterologous BoHV-1 isolate. Thus, this immunization strategy may be considered for the prevention of BoHV-1-associated genital disease in the field. |
publishDate |
2009 |
dc.date.issued.fl_str_mv |
2009-03-03 |
dc.date.accessioned.fl_str_mv |
2017-06-14 |
dc.date.available.fl_str_mv |
2017-06-14 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
WEISS, Marcelo. Genital immunization of heifers with a recombinant strain of bovine herpesvirus type 1 defective in the glycoprotein E. 2009. 42 f. Dissertação (Mestrado em Medicina Veterinária) - Universidade Federal de Santa Maria, Santa Maria, 2009. |
dc.identifier.uri.fl_str_mv |
http://repositorio.ufsm.br/handle/1/10035 |
identifier_str_mv |
WEISS, Marcelo. Genital immunization of heifers with a recombinant strain of bovine herpesvirus type 1 defective in the glycoprotein E. 2009. 42 f. Dissertação (Mestrado em Medicina Veterinária) - Universidade Federal de Santa Maria, Santa Maria, 2009. |
url |
http://repositorio.ufsm.br/handle/1/10035 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.cnpq.fl_str_mv |
500500000007 |
dc.relation.confidence.fl_str_mv |
400 500 500 500 500 |
dc.relation.authority.fl_str_mv |
1cd49172-b6b6-4db1-b27e-daf2b145ba82 d5f9666a-b82e-4a5c-96d1-3b2f85651db0 0aa5402c-d907-49de-b28f-597e39e788d7 c648a19e-e9b3-43c3-95bf-791bb03d4b80 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade Federal de Santa Maria |
dc.publisher.program.fl_str_mv |
Programa de Pós-Graduação em Medicina Veterinária |
dc.publisher.initials.fl_str_mv |
UFSM |
dc.publisher.country.fl_str_mv |
BR |
dc.publisher.department.fl_str_mv |
Medicina Veterinária |
publisher.none.fl_str_mv |
Universidade Federal de Santa Maria |
dc.source.none.fl_str_mv |
reponame:Manancial - Repositório Digital da UFSM instname:Universidade Federal de Santa Maria (UFSM) instacron:UFSM |
instname_str |
Universidade Federal de Santa Maria (UFSM) |
instacron_str |
UFSM |
institution |
UFSM |
reponame_str |
Manancial - Repositório Digital da UFSM |
collection |
Manancial - Repositório Digital da UFSM |
bitstream.url.fl_str_mv |
http://repositorio.ufsm.br/bitstream/1/10035/1/MARCELOWEISS.pdf http://repositorio.ufsm.br/bitstream/1/10035/2/MARCELOWEISS.pdf.txt http://repositorio.ufsm.br/bitstream/1/10035/3/MARCELOWEISS.pdf.jpg |
bitstream.checksum.fl_str_mv |
66fd01e5afabbdf077cac1995145c39f 39de5878e532784c61abecd9127f7077 a6a8b3a4f4fdb063c5131eae8d03eaac |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
repository.name.fl_str_mv |
Manancial - Repositório Digital da UFSM - Universidade Federal de Santa Maria (UFSM) |
repository.mail.fl_str_mv |
|
_version_ |
1794524371249790976 |